Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Recruiting now · Phase 2
Conditions studied: Melanoma, Squamous Cell Carcinoma of Head and Neck
In brief
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.
Key facts
- Study ID
- NCT05280314
- Run by
- IO Biotech
- People needed
- 60
- Starts
- 2023-12-21
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2024-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Yale — New Haven, Connecticut, United States (enrolling)
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Massey Cancer Center — Richmond, Virginia, United States (enrolling)
- Melanoma Institute Australia The Uiniversity of Sydney, and Royal North Shore Hospital — Sydney, New South Wales, Australia (enrolling)
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia (enrolling)
- Aarhus University Hospital — Aarhus, Denmark (enrolling)
- Copenhagen University Hospital Herlev — Copenhagen, Denmark (enrolling)
- CHRU Lille — Lille, France (enrolling)
- Hôpital Ambroise-Paré — Paris, France (enrolling)
- Institut Gustave Roussy — Paris, France (enrolling)
- Universitätsklinikum Essen & Research Alliance Ruhr — Essen, Germany (enrolling)
- Universität Heidelberg, Medizinische Fakultät — Heidelberg, Germany (enrolling)
- Hospital Universitario Quirón Dexeus — Barcelona, Spain (enrolling)
- Hospital Universitario Ramón y Cajal — Madrid, Spain (enrolling)
- Hospital Clínico Universitario de Valencia -INCLIVA — Valencia, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.